Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBT101 intrathecal gene therapy study in adults with adrenomyeloneuropathy
NL-OMON56436Phase 2Recruiting
- Sponsor
- SwanBio Therapeutics
- Start
- Oct 2023
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SBT101 in adrenomyeloneuropathy (AMN) and adrenoleukodystrophy (ALD) (4 arms), sponsored by SwanBio Therapeutics. Primary endpoint: Grade III or Grade IV treatment-related adverse events by Month 24. Started Oct 2023; status: recruiting.
02
Drugs
SBT101
03
Conditions
adrenomyeloneuropathy (AMN)adrenoleukodystrophy (ALD)
Beyond the preview
Go deeper on NL-OMON56436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56436.